Brain-derived neurotrophic factor plasma levels are increased in older women after an acute episode of low back pain

Background. Serotonin and brain-derived neurotrophic factor (BDNF) are known to be modulators of nociception. However, pain-related connection between yoga and those neuromodulators has not been investigated. Therefore, we aimed to evaluate the effect of yoga on pain, BDNF, and serotonin.Methods. Premenopausal women with chronic low back pain practiced yoga three times a week for 12 weeks. At baseline and after 12 weeks, back pain intensity was measured using visual analogue scale (VAS), and serum BDNF and serotonin levels were evaluated. Additionally, back flexibility and level of depression were assessed.Results. After 12-week yoga, VAS decreased in the yoga group (P<0.001), whereas it increased (P<0.05) in the control group. Back flexibility was improved in the yoga group (P<0.01). Serum BDNF increased in the yoga group (P<0.01), whereas it tended to decrease in the control group (P=0.05). Serum serotonin maintained in the yoga group, while it reduced (P<0.01) in the control group. The depression level maintained in the yoga group, whereas it tended to increase in the control group (P=0.07).Conclusions. We propose that BDNF may be one of the key factors mediating beneficial effects of yoga on chronic low back pain.

Download Full-text

Brain - Derived Neurotrophic Factor - a Marker for the Balneal Treatment of Chronic Low Back Pain?

Revista de Chimie ◽

10.37358/rc.19.9.7511 ◽

2019 ◽

Vol 70 (9) ◽

pp. 3180-3184 ◽

Cited By ~ 3

Author(s):

Irina Tica ◽

Andreea Lupu ◽

Mihaela Botnarciuc ◽

Lucian Petcu ◽

Carmen Oprea ◽

...

Keyword(s):

Neuropathic Pain ◽

Low Back Pain ◽

Back Pain ◽

Physical Exercise ◽

Chronic Low Back Pain ◽

Neurotrophic Factor ◽

Serum Levels ◽

Brain Derived Neurotrophic Factor ◽

Low Back ◽

Important Mediator

Up till now, to our knowledge, there are no studies evaluating serum Brain - Derived Neurotrophic Factor (BDNF) levels in patients with degenerative chronic low back pain under rehabilitation treatment. BDNF is a neuroprotein associated with neuropathic pain and represents an important mediator of the effects of physical exercise. Complex balneal treatment with hot Techirghiol sapropelic mud reduces pain and increases serum levels of BDNF in these patients.

Download Full-text

The genetic influence of the brain-derived neurotrophic factor Val66Met polymorphism in chronic low back pain

Advances in Rheumatology ◽

10.1186/s42358-021-00183-7 ◽

2021 ◽

Vol 61 (1) ◽

Author(s):

Angela Shiratsu Yamada ◽

Flavia Tasmim Techera Antunes ◽

Camila Ferraz ◽

Alessandra Hubner de Souza ◽

Daniel Simon

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Chronic Low Back Pain ◽

Neurotrophic Factor ◽

Central Sensitization ◽

Low Back ◽

Bdnf Gene ◽

Val66met Polymorphism ◽

Bdnf Val66met Polymorphism ◽

The Brain

Abstract Background The Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene is a potential biomarker of vulnerability to pain. Thus, the present study aimed to investigate the association of this polymorphism with clinical and biopsychosocial factors in patients with chronic low back pain (CLBP). Methods A total of 107 individuals with CLBP answered questionnaires that were validated and adapted for the Brazilian population, including the Brief Inventory of Pain, the Central Sensitization Inventory, the Roland Morris Disability Questionnaire, the Tampa Scale for Kinesiophobia, the Pain Catastrophizing Scale, the Survey of Pain Attitude-Brief, and the Hospital Anxiety and Depression Scale. All of the subjects were genotyped for the BDNF Val66Met polymorphism. Results The sample showed moderate scores of disability, central sensitization, and kinesiophobia, in addition to mild anxiety, hopelessness, and ruminant thoughts. No significant association was observed between the Val66Met polymorphism and the variables analyzed. Besides, there was no relationship between the BDNF Val66Met polymorphism with CSI, catastrophization, or disabilities that were generated by CLBP. Conclusion The results showed that the Val66Met polymorphism of the BDNF gene was not associated with clinical and biopsychosocial characteristics of CLBP in the sample studied.

Download Full-text

Inflammatory mediators and the risk of falls among older women with acute low back pain: data from Back Complaints in the Elders (BACE)—Brazil

European Spine Journal ◽

10.1007/s00586-019-06168-x ◽

2019 ◽

Vol 29 (3) ◽

pp. 549-555

Author(s):

Bárbara Zille de Queiroz ◽

Nayza Maciel de Britto Rosa ◽

Daniele Sirineu Pereira ◽

Renata Antunes Lopes ◽

Amanda Aparecida Oliveira Leopoldino ◽

...

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Older Women ◽

Inflammatory Mediators ◽

Low Back ◽

Acute Low Back Pain ◽

Risk Of Falls

Download Full-text

Effect of a Simple Information Booklet on Pain Persistence after an Acute Episode of Low Back Pain: A Non-Randomized Trial in a Primary Care Setting

PLoS ONE ◽

10.1371/journal.pone.0000706 ◽

2007 ◽

Vol 2 (8) ◽

pp. e706 ◽

Cited By ~ 46

Author(s):

Emmanuel Coudeyre ◽

Florence Tubach ◽

François Rannou ◽

Gabriel Baron ◽

Fernand Coriat ◽

...

Keyword(s):

Primary Care ◽

Low Back Pain ◽

Back Pain ◽

Randomized Trial ◽

Care Setting ◽

Primary Care Setting ◽

Acute Episode ◽

Low Back ◽

Information Booklet

Download Full-text

Onset of analgesic effect and plasma levels of controlled-release tramadol (Tramadol Contramid once-a-day) 200-mg tablets in patients with acute low back pain

Journal of Opioid Management ◽

10.5055/jom.2008.0032 ◽

2018 ◽

Vol 4 (5) ◽

pp. 285 ◽

Cited By ~ 7

Author(s):

Adrian Sarbu, MD ◽

Florin Radulescu, MD ◽

Sybil Robertson, BScN ◽

Sylvie Bouchard, MD, PhD

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Controlled Release ◽

Pain Relief ◽

Plasma Levels ◽

Immediate Release ◽

Pharmacokinetic Profile ◽

Low Back ◽

Acute Low Back Pain ◽

Therapeutic Threshold

Background and Aims: Tramadol hydrochloride, a centrally acting, synthetic analgesic, has been available in Europe since 1977 in a variety of formulations and in the United States since 1995. Its clinical efficacy was established in a variety of painful conditions (cancer pain, neuropathic pain, and osteoarthritis). Nonetheless, little published data exist regarding the relationship between analgesic onset and minimum therapeutic plasma levels. Tramadol Contramid* once-a-day (OAD) demonstrates a pharmacokinetic profile with a sharp initial absorption slope similar to the pharmacokinetic profile of the immediate- release tramadol, suggesting that both the immediaterelease and the once-daily (Contramid) formulation may produce a similar onset of analgesia.Methods: This multicentre, open-label, single-dose study examined the pharmacokinetics/pharmacodynamics of Tramadol Contramid OAD in patients with acute low back pain. Patients who signed informed consent were screened and washed-out of prior analgesics. Patients received one dose of Tramadol Contramid OAD 200 mg. The patients indicated the time of onset of pain relief (stopwatch method). Ratings of pain intensity and pain relief and pharmacokinetic samples were taken prior to dosing, at the onset of pain relief, and 3 and 6 hours postdose. No rescue medication was permitted until the end of the study (6-hour postdose). Adverse events were monitored throughout the study.Results: Forty of the 47 patients enrolled completed the study. Onset of perceptible pain relief was achieved within 1 hour for the majority of patients and at plasma levels, suggesting a therapeutic threshold between 50 and 100 ng/mL. Two patients did not experience any pain relief.Conclusions: The results of this exploratory study suggest that similar to immediate-release tramadol, onset of analgesia for this controlled-release formulation of tramadol (Tramadol Contramid OAD) occurs within 1 hour at a mean therapeutic threshold concentration of 56 ± 38 ng/mL.

Download Full-text